Clinical Trial Update: MET/VEGFR2 Inhibitor GSK1363089 and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone in Locally Advanced or Metastatic NSCLC That Has Not Responded to Previous Chemotherapy [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for a MET/VEGFR2 inhibitor (GSK1363089) with or without erlotinib in locally advanced or metastatic non-small cell lung cancer that failed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Erlotinib hydrochloride (Erlotinib)
• GSK1363089 (GSK1363089)

Snippet

Sponsor: NCIC Clinical Trials Group | Conditions: Lung Cancer | Phase 1, Phase 2 | Status: COMPLETED